TriangleLABELS · b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
Doxorubicin Hydrochloride
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-04-30
- Captured
- 2026-09-09T23:37:58.719708+00:00
- Current indication reconciliation
- Not reconciled
Boxed warning in this label
- WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1%–20% for cumulative doses ranging from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride [see Warnings and Precautions (5.2) ] . • Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area [see Warnings and Precautions (5.3) ] . • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions (5.4) ] . WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. • Cardiomyopathy: Myocardial damage can occur with doxorubicin hydrochloride with incidences from 1%–20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride. ( 5.1 ) • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride. ( 5.2 ) • Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision and skin grafting. Immediately terminate the drug, and apply ice to the affected area. ( 5.3 ) • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. ( 5.4 )
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
Full extracted label fields
- application numbers
- NDA050629
- boxed warning exact
- WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1%–20% for cumulative doses ranging from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride [see Warnings and Precautions (5.2) ] . • Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area [see Warnings and Precautions (5.3) ] . • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions (5.4) ] . WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. • Cardiomyopathy: Myocardial damage can occur with doxorubicin hydrochloride with incidences from 1%–20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride. ( 5.1 ) • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride. ( 5.2 ) • Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision and skin grafting. Immediately terminate the drug, and apply ice to the affected area. ( 5.3 ) • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. ( 5.4 )
- brand names
- Doxorubicin Hydrochloride
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00634b2b-4e48-4178-8877-28582af894ad
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- indications and usage exact
- 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Pfizer Laboratories Div Pfizer Inc
- matched search terms
- cancer
- carcinoma
- lymphoma
- leukemia
- sarcoma
- sarcomas
- tumor
- neuroblastoma
- package ndcs
- 0069-4004-05
- 0069-4015-10
- 0069-4026-25
- 0069-4037-01
- 0069-4205-05
- 0069-0255-10
- 0069-3358-25
- 0069-1442-04
- product ndcs
- 0069-0255
- 0069-4004
- 0069-4015
- 0069-4026
- 0069-4037
- 0069-4205
- 0069-3358
- 0069-1442
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- record type
- complete_spl_indications_section_candidate
- routes
- INTRAVENOUS
- rxcuis
- 1191138
- 1790097
- 1790099
- 1790100
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00600.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 600
- total
- 830
- sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl effective time
- 20260430
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- substance names
- DOXORUBICIN HYDROCHLORIDE
- uniis
- 82F2G7BL4E
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
Drugs@FDA application source records
- application number
- NDA050629
- payload
- all indexed label documents
- Appl No
- 050629
- Application Docs Date
- 2002-09-25 00:00:00
- Application Docs ID
- 17949
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50467s64s67,50629s10s13lbl.pdf
- Submission No
- 10
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2003-05-13 00:00:00
- Application Docs ID
- 17950
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/050467s068lbl.pdf
- Submission No
- 14
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2003-05-29 00:00:00
- Application Docs ID
- 17951
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50629se1-014slr016,50467se1-068,slr069_doxorubicin_lbl.pdf
- Submission No
- 16
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2010-07-30 00:00:00
- Application Docs ID
- 17952
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050629s017lbl.pdf
- Submission No
- 17
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2011-09-26 00:00:00
- Application Docs ID
- 17953
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050629s019lbl.pdf
- Submission No
- 19
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2013-11-01 00:00:00
- Application Docs ID
- 17954
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050629s022lbl.pdf
- Submission No
- 22
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2002-09-25 00:00:00
- Application Docs ID
- 39053
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50467s64s67,50629s10s13lbl.pdf
- Submission No
- 13
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2019-08-12 00:00:00
- Application Docs ID
- 59661
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050629s029lbl.pdf
- Submission No
- 29
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2019-12-23 00:00:00
- Application Docs ID
- 61393
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050629s028lbl.pdf
- Submission No
- 28
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2020-10-29 00:00:00
- Application Docs ID
- 65072
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf
- Submission No
- 30
- Submission Type
- SUPPL
- Appl No
- 050629
- Application Docs Date
- 2024-05-15 00:00:00
- Application Docs ID
- 78469
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050629Orig1s033Correctedlbl.pdf
- Submission No
- 33
- Submission Type
- SUPPL
- all submission records
- Appl No
- 050629
- Review Priority
- N/A
- Submission Class Code ID
- 4
- Submission No
- 33
- Submission Status
- AP
- Submission Status Date
- 2024-05-09 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 30
- Submission Status
- AP
- Submission Status Date
- 2020-08-28 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 29
- Submission Status
- AP
- Submission Status Date
- 2019-08-09 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 28
- Submission Status
- AP
- Submission Status Date
- 2019-12-20 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- PRIORITY
- Submission Class Code ID
- 4
- Submission No
- 25
- Submission Status
- AP
- Submission Status Date
- 2014-12-05 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- PRIORITY
- Submission Class Code ID
- 4
- Submission No
- 24
- Submission Status
- AP
- Submission Status Date
- 2013-10-23 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- PRIORITY
- Submission Class Code ID
- 4
- Submission No
- 23
- Submission Status
- AP
- Submission Status Date
- 2013-10-10 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 22
- Submission Status
- AP
- Submission Status Date
- 2013-10-31 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- UNKNOWN
- Submission Class Code ID
- 3
- Submission No
- 19
- Submission Status
- AP
- Submission Status Date
- 2011-09-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- N/A
- Submission Class Code ID
- 4
- Submission No
- 18
- Submission Status
- AP
- Submission Status Date
- 2011-03-28 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- UNKNOWN
- Submission Class Code ID
- 3
- Submission No
- 17
- Submission Status
- AP
- Submission Status Date
- 2010-07-30 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 050629
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 16
- Submission Status
- AP
- Submission Status Date
- 2003-05-08 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- NDA050629
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050629
- has approved submission record
- true
- latest approved submission date
- 2024-05-09
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 050629
- Application Docs Date
- 2024-05-15 00:00:00
- Application Docs ID
- 78469
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050629Orig1s033Correctedlbl.pdf
- Submission No
- 33
- Submission Type
- SUPPL
- official application record
- Appl No
- 050629
- Appl Public Notes
- Appl Type
- NDA
- Sponsor Name
- PFIZER
- openfda application present
- true
- products
- Active Ingredient
- DOXORUBICIN HYDROCHLORIDE
- Appl No
- 050629
- Drug Name
- DOXORUBICIN HYDROCHLORIDE
- Form
- INJECTABLE;INJECTION
- Product No
- 001
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- 2MG/ML
- marketing status
- Prescription
- Active Ingredient
- DOXORUBICIN HYDROCHLORIDE
- Appl No
- 050629
- Drug Name
- DOXORUBICIN HYDROCHLORIDE
- Form
- INJECTABLE;INJECTION
- Product No
- 002
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- 200MG/100ML
- marketing status
- Prescription
- Active Ingredient
- DOXORUBICIN HYDROCHLORIDE
- Appl No
- 050629
- Drug Name
- DOXORUBICIN HYDROCHLORIDE
- Form
- INJECTABLE;INJECTION
- Product No
- 003
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- 150MG/75ML
- marketing status
- Discontinued
Source passages and status connections
Passage 1 · indication intro context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- incomplete_colon_led_indication_intro
- clinical review status
- pending
- content role
- indication_intro_context
- context span
- end
- 314
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute ly
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-894cde1e1c5138b80a5d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-06229440671085313891
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- end
- 113
- end exclusive
- true
- exact text
- is an anthracycline topoisomerase inhibitor indicated
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 60
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 114
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated:
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 2 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 481
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma,
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-a2cbce86f0a1e2ee66a9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-99851a4431c006c0406c
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection o
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 190
- end exclusive
- true
- exact text
- adjuvant chemotherapy for treatment of wome
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 147
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 281
- end exclusive
- true
- exact text
- • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 )
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 115
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 3 · positive indication candidate
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 919
- end exclusive
- true
- exact text
- poisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following r
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 82
- current approval status
- not_reconciled
- duplicate text group
- dup-b2e4bea231a88f63fce6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-b5f044c4a21e0987f561
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- end
- 113
- end exclusive
- true
- exact text
- is an anthracycline topoisomerase inhibitor indicated
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 60
- qualifier mentions
- context exact
- loblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metasta
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 429
- end exclusive
- true
- exact text
- metastatic breast cancer
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 405
- context exact
- n lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma,
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 454
- end exclusive
- true
- exact text
- metastatic Wilms' tumor
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 431
- context exact
- ymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas,
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 480
- end exclusive
- true
- exact text
- metastatic neuroblastoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 456
- context exact
- cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, me
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 512
- end exclusive
- true
- exact text
- metastatic soft tissue sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 482
- context exact
- , metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 538
- end exclusive
- true
- exact text
- metastatic bone sarcomas
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 514
- context exact
- , metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 568
- end exclusive
- true
- exact text
- metastatic ovarian carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 540
- context exact
- ma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcin
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 613
- end exclusive
- true
- exact text
- metastatic transitional cell bladder carcin
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 570
- context exact
- carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carc
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 646
- end exclusive
- true
- exact text
- metastatic thyroid carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 618
- context exact
- ional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 )
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 676
- end exclusive
- true
- exact text
- metastatic gastric carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 648
- context exact
- metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 )
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 715
- end exclusive
- true
- exact text
- metastatic bronchogenic carcinoma ( 1
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 678
- context exact
- loblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metasta
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 429
- end exclusive
- true
- exact text
- metastatic breast cancer
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 405
- context exact
- n lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma,
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 454
- end exclusive
- true
- exact text
- metastatic Wilms' tumor
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 431
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 719
- end exclusive
- true
- exact text
- • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 )
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 282
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 4 · positive indication candidate
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1154
- end exclusive
- true
- exact text
- atic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) •
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 520
- current approval status
- not_reconciled
- duplicate text group
- dup-b4aec5f7ed7e647583c7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-1de0a4d0d38be9f7c0f0
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- end
- 795
- end exclusive
- true
- exact text
- is indicated
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 783
- qualifier mentions
- context exact
- 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent a
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 767
- end exclusive
- true
- exact text
- Adjuvant Breast Cancer Doxorubicin Hydrochl
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 724
- context exact
- loride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection o
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 869
- end exclusive
- true
- exact text
- adjuvant chemotherapy for treatment of wome
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 826
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 954
- end exclusive
- true
- exact text
- 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer .
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 720
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 5 · positive indication candidate
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1242
- end exclusive
- true
- exact text
- cin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastat
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 755
- current approval status
- not_reconciled
- duplicate text group
- dup-00d8e82c2949d41cceca
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-c1802181a78889739fe9
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- end
- 1021
- end exclusive
- true
- exact text
- is indicated
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1009
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1042
- end exclusive
- true
- exact text
- 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 955
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 6 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1273
- end exclusive
- true
- exact text
- rapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metast
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 843
- current approval status
- not_reconciled
- duplicate text group
- dup-509ad612e4792745998e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-24f5f1ca8174ecceca00
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1073
- end exclusive
- true
- exact text
- • acute lymphoblastic leukemia
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1043
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1303
- end exclusive
- true
- exact text
- h axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 874
- current approval status
- not_reconciled
- duplicate text group
- dup-b7536540825332dcafc7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-aff5f2ca2ae27851cc35
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1103
- end exclusive
- true
- exact text
- • acute myeloblastic leukemia
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1074
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1322
- end exclusive
- true
- exact text
- ent following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 904
- current approval status
- not_reconciled
- duplicate text group
- dup-5642bdd24c94bd8fbb06
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-8cfea3834d489c0032a6
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1122
- end exclusive
- true
- exact text
- • Hodgkin lymphoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1104
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1351
- end exclusive
- true
- exact text
- tion of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cel
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 923
- current approval status
- not_reconciled
- duplicate text group
- dup-c31d3b0c7ef015aac9c3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-c3b21f9f922d6726e9e5
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1151
- end exclusive
- true
- exact text
- • non-Hodgkin lymphoma (NHL)
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1123
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1378
- end exclusive
- true
- exact text
- . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metas
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 952
- current approval status
- not_reconciled
- duplicate text group
- dup-2d7856ad583e546c67a3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-ab06d2d1a7aae0116e9b
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic breast cancer
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1178
- end exclusive
- true
- exact text
- metastatic breast cancer
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1154
- context exact
- • metastatic breast cancer
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1178
- end exclusive
- true
- exact text
- metastatic breast cancer
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1154
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1178
- end exclusive
- true
- exact text
- • metastatic breast cancer
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1152
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1404
- end exclusive
- true
- exact text
- bicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma •
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 979
- current approval status
- not_reconciled
- duplicate text group
- dup-069dc475d7bc1bd7df89
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-77532b2abd4ae765272b
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic Wilms' tumor
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1204
- end exclusive
- true
- exact text
- metastatic Wilms' tumor
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1181
- context exact
- • metastatic Wilms' tumor
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1204
- end exclusive
- true
- exact text
- metastatic Wilms' tumor
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1181
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1204
- end exclusive
- true
- exact text
- • metastatic Wilms' tumor
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1179
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1431
- end exclusive
- true
- exact text
- ion is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinom
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1005
- current approval status
- not_reconciled
- duplicate text group
- dup-542e24703a622f5d0e0d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-ab63b7b1e0ce44431d2b
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic neuroblastoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1231
- end exclusive
- true
- exact text
- metastatic neuroblastoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1207
- context exact
- • metastatic neuroblastoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1231
- end exclusive
- true
- exact text
- metastatic neuroblastoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1207
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1231
- end exclusive
- true
- exact text
- • metastatic neuroblastoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1205
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1464
- end exclusive
- true
- exact text
- eatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carci
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1032
- current approval status
- not_reconciled
- duplicate text group
- dup-c5721f8cca0dffb9638b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-295e704eef99fad425f9
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic soft tissue sarcoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1264
- end exclusive
- true
- exact text
- metastatic soft tissue sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1234
- context exact
- • metastatic soft tissue sarcoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1264
- end exclusive
- true
- exact text
- metastatic soft tissue sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1234
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1264
- end exclusive
- true
- exact text
- • metastatic soft tissue sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1232
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1468
- end exclusive
- true
- exact text
- leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1065
- current approval status
- not_reconciled
- duplicate text group
- dup-b49f02b4445691f5b0ca
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-17ae739ec343b76c1e00
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic bone sarcoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1290
- end exclusive
- true
- exact text
- metastatic bone sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1267
- context exact
- • metastatic bone sarcoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1290
- end exclusive
- true
- exact text
- metastatic bone sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1267
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1290
- end exclusive
- true
- exact text
- • metastatic bone sarcoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1265
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1468
- end exclusive
- true
- exact text
- tic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1091
- current approval status
- not_reconciled
- duplicate text group
- dup-524cebb4d4c2552fec56
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-e9323bd954f28db8c99f
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic ovarian carcinoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1321
- end exclusive
- true
- exact text
- metastatic ovarian carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1293
- context exact
- • metastatic ovarian carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1321
- end exclusive
- true
- exact text
- metastatic ovarian carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1293
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1321
- end exclusive
- true
- exact text
- • metastatic ovarian carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1291
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1468
- end exclusive
- true
- exact text
- • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1122
- current approval status
- not_reconciled
- duplicate text group
- dup-e0ecca7dfd2670fb6ea7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-50378b047560abd61695
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic transitional cell bladder carcinoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1367
- end exclusive
- true
- exact text
- metastatic transitional cell bladder carcin
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1324
- context exact
- • metastatic transitional cell bladder carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1369
- end exclusive
- true
- exact text
- metastatic transitional cell bladder carcinom
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1324
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1370
- end exclusive
- true
- exact text
- • metastatic transitional cell bladder carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1322
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1468
- end exclusive
- true
- exact text
- cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1171
- current approval status
- not_reconciled
- duplicate text group
- dup-44210817f84777d30cea
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-3da2b56f3865fa5549ce
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic thyroid carcinoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1401
- end exclusive
- true
- exact text
- metastatic thyroid carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1373
- context exact
- • metastatic thyroid carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1401
- end exclusive
- true
- exact text
- metastatic thyroid carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1373
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1401
- end exclusive
- true
- exact text
- • metastatic thyroid carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1371
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1468
- end exclusive
- true
- exact text
- or • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1202
- current approval status
- not_reconciled
- duplicate text group
- dup-c58ef3200ee75a851464
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-c8e55c568a9b1ad6c3de
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic gastric carcinoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1432
- end exclusive
- true
- exact text
- metastatic gastric carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1404
- context exact
- • metastatic gastric carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1432
- end exclusive
- true
- exact text
- metastatic gastric carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1404
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1432
- end exclusive
- true
- exact text
- • metastatic gastric carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1402
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · unclassified context
- application numbers
- NDA050629
- brand names
- Doxorubicin Hydrochloride
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1468
- end exclusive
- true
- exact text
- metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1233
- current approval status
- not_reconciled
- duplicate text group
- dup-a3907f77a63d222f45cc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- DOXORUBICIN HYDROCHLORIDE
- id
- ind-span-8f7ae5f56a8087697063
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • metastatic bronchogenic carcinoma
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1468
- end exclusive
- true
- exact text
- metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1435
- context exact
- • metastatic bronchogenic carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1468
- end exclusive
- true
- exact text
- metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1435
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1468
- end exclusive
- true
- exact text
- • metastatic bronchogenic carcinoma
- label id
- b4c94e1f-f7c7-4b4b-9fe2-111903c0d312
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 9a2c231a5270d5e604bfd7dc4fc4c294cc7e955801cf41bab5525c23719d3292
- start
- 1433
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22b4c94e1f-f7c7-4b4b-9fe2-111903c0d312%22
- spl effective date
- 2026-04-30
- spl set id
- 00634b2b-4e48-4178-8877-28582af894ad
- spl version
- 14
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Preserved source evidence · Not medical advice